Jefferies Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Jefferies Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$342K	–	1668
2025 Q2	$342K	Buy	+20,000	New	+$853K	﹤0.01%	985
2024 Q1	–	Sell	-5,000	Closed	-$482K	–	2008
2023 Q4	$482K	Hold	5,000	–	–	﹤0.01%	1239
2023 Q3	$606K	Hold	5,000	–	–	0.01%	1000
2023 Q2	$573K	Sell	5,000 -17,500	-78%	-$2.26M	0.01%	1135
2023 Q1	$3.1M	Sell	22,500 -43,000	-66%	-$5.58M	0.03%	514
2022 Q4	$8.49M	Buy	+65,500	New	+$7.59M	0.06%	249

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Financial Group's SRPT Position: Q1 2026 in Review

Jefferies Financial Group opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 78,980 shares worth $1.72M. The stake represents 0.01% of the portfolio and ranks #691 among its holdings. This is a return to the name: Jefferies Financial Group previously reported a position in SRPT as recently as Q2 2025.

Jefferies Financial Group first reported a position in SRPT in Q4 2022 and has held it in 7 quarters since. The position peaked at $8.98M in Q4 2022. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Jefferies Financial Group held 78,980 shares of Sarepta Therapeutics worth $1.72M as of Q1 2026.
Sarepta Therapeutics was a new Jefferies Financial Group position in Q1 2026.
Sarepta Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #691 holding.
Jefferies Financial Group first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 7 quarters since.
Jefferies Financial Group's Sarepta Therapeutics position peaked at $8.98M in Q4 2022.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.